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Clinical Summary
Cardiac arrest results in significant morbidity and mortality driven mainly by the cardiac and neurological injury resulting from global
ischemia and reperfusion injury. Although resuscitation rates can exceed 65% for some rhythms, between 50-75% of these patients will
die before hospital discharge and up to a third of survivors will suffer significant brain injury. Only hypothermia has shown clinical
benefit as a post-resuscitation therapy in a subset of patients. Clearly additional therapies are needed. The recent finding that nitrite acts
as an ischemic reservoir for enzyme independent nitric oxide generation has resulted in numerous animal studies where it has proven
beneficial in reducing focal ischemic organ injury. Based on promising results in focal heart and brain ischemia, Dezfulian et al. have
adapted a mouse model of cardiac arrest to model the high clinical mortality and myocardial and neurological dysfunction associated
with cardiac arrest. Within this model, nitrite therapy given at the start of resuscitation resulted in significant improvements in survival
and myocardial and neurological function in survivors. The authors further investigate the potential mechanism for cardioprotection
which involves nitrite’s role as a mitochondrial antioxidant early in resuscitation. The significant benefits attributed to nitrite, along with
its ease of delivery and known primate and human safety data make this a promising therapy for a condition with few current therapeutic
options.
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Abstract
Background—Three-fourths of cardiac arrest survivors die prior to hospital discharge or suffer
significant neurological injury. Excepting therapeutic hypothermia and revascularization, no novel
therapies have been developed that improve survival or cardiac and neurological function after
resuscitation. Nitrite (NO2−) increases cellular resilience to focal ischemia-reperfusion injury in
multiple organs. We hypothesized that nitrite therapy may improve outcomes after the unique global
ischemia-reperfusion insult of cardiopulmonary arrest.
Methods and Results—We developed a mouse model of cardiac arrest characterized by 12-
minutes of normothermic asystole and a high cardiopulmonary resuscitation (CPR) rate. In this
model, global ischemia and CPR was associated with blood and organ nitrite depletion, reversible
myocardial dysfunction, impaired alveolar gas exchange, neurological injury and an approximate
50% mortality. A single low dose of intravenous nitrite (50 nmol=1.85 μmol/kg=0.13 mg/kg)
compared to blinded saline placebo given at CPR initiation with epinephrine improved cardiac
function, survival and neurological outcomes. From a mechanistic standpoint, nitrite treatment
restored intracardiac nitrite and increased S-nitrosothiol levels, decreased pathological cardiac
mitochondrial oxygen consumption due to reactive oxygen species formation and prevented
oxidative enzymatic injury via reversible specific inhibition of respiratory chain complex I.
Conclusion—Nitrite therapy after resuscitation from 12-minutes of asystole rapidly and reversibly
modulated mitochondrial reactive oxygen species generation during early reperfusion, limiting acute
cardiac dysfunction and death, as well as neurological impairment in survivors.
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Introduction
Nitrite (NO2−), historically considered inert, functions as a reservoir for nitric oxide (NO) 1.
During physiological hypoxia and pathological ischemia, nitrite is reduced to NO regulating
hypoxic vasodilation, cellular respiration, mitochondrial reactive oxygen species (ROS)
generation, angiogenesis2, and cellular death programs3. Nitrite in human plasma exists at
concentrations of 100–300 nM3–5 and may be reduced to NO by iron-containing enzymes3,
6 including hemoglobin, myoglobin, neuroglobin, xanthine oxidoreductase, endothelial NO
synthase, mitochondrial electron transport chain proteins and the hepatic cytochrome P450
system. The rate and extent of nitrite reduction is coupled to deoxygenation and proton
generation. Thus NO generation is coupled to oxygen and pH gradients3, 7 and maximized in
ischemic tissues.
Nitrite therapy limits cellular injury and apoptosis after ischemia and reperfusion6. Nitrite
therapy is cytoprotective in numerous animal models of focal ischemia-reperfusion injury6
including rodent heart8, brain9, liver8 and kidney, canine heart10 and primate brain11. Systemic
nitrite reduction by ceruloplasmin knockout12 or dietary nitrate/nitrite elimination13 increased
infarction volume in the liver and heart after experimental ischemia. These studies indicate
that physiological systemic nitrite levels modulate host resilience to ischemia. The established
safety of human and animal nitrite dosing14 and its potent effects in limiting major organ injury
suggest that nitrite represents an ideal therapy for cardiac arrest.
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Cardiac arrest results in global multi-organ ischemic injury associated with significant
morbidity and mortality15, 16. Over 70% of those resuscitated die prior to hospital
discharge15, 16. Excepting the selective application of hypothermia and revascularization, no
novel post-resuscitation therapies have been developed that improve survival or cardiac and
neurological function15. We explored nitrite therapy in a mouse model of cardiac arrest. We
show evidence that nitrite therapy improves cardiac function, survival and neurological
function in survivors. Mechanistically, we show that nitrite specifically and reversibly inhibits
cardiac complex I, limiting oxidative reperfusion injury. Nitrite’s ease of delivery, established
human safety and efficacy in murine cardiac arrest suggest its promise as a novel therapy after
cardiac arrest.
Methods
Mouse Cardiac Arrest Model
In initial model building we adapted mouse cardiac arrest models from prior reports17, 18 with
the goal of nearly 100% resuscitation and 50% 24 hour mortality. To modulate mortality we
extended asystolic time from 8 to 12 minutes and added epinephrine to increase return of
spontaneous circulation (ROSC). Seven to twelve week old (24–30g) C57BL/6 male mice were
used as approved by the NIH IACUC. Anesthesia intraperitoneal ketamine/xylazine (100/15
mg/kg respectively) preceded surgical preparation consisting of orotracheal intubation and
placement of right carotid and jugular catheters. Ventilation (ASV, Harvard Instruments,
Cambridge, MA) for 10 minutes (minimum) at a rate of 110 bpm and a volume of 15 ml/kg
preceded cardiac arrest and produced normal blood gases (Table 1). EKG, arterial blood
pressure, exhaled carbon dioxide and rectal temperature were recorded at baseline and during
60 minutes post-resuscitation (Powerlab, ADInstruments, Colorado Springs, CO). Asystole
was induced by 100 μl potassium chloride (0.09 g/kg; minimum 2.5% [w/v]) IV bolus and
temperature maintained at 36.5°C for 12 minutes. Cardiopulmonary resuscitation (CPR) was
performed with rapid (375–425) finger compressions, resumption of mechanical ventilation
(25% tidal volume increase) and 10 μg IV epinephrine (500 μl) prior to CPR and 2 μg (100
μl) 1 minute post-CPR. Animals received either 50 nmol (1.85μmol/kg=0.13 mg/kg,) sodium
nitrite (in 0.9% saline) or saline placebo IV in randomized, blinded fashion at CPR initiation.
This dose and timing of delivery were based on prior work8.
To minimize variability we paired inbred animals to nitrite or placebo based on similar weight,
sex, age, delivery date and where possible holding cage. Pairing appeared effective (Table 2).
Post-resuscitation care was uniform between groups. A model summary is provided as Figure
1. Sham control animals received anesthesia, surgery and ventilation but no cardiac arrest and
the same post-resuscitation care until the similarly timed endpoint. Shams were drawn from
the same batch as experimental animals.
Blood Gases and Blood/Tissue Nitrite Levels
Carotid arterial blood was obtained in a heparinized syringe either 55 minutes after anesthesia
(sham) or 5 minutes after CPR. Blood was utilized for blood gas analysis (Nova Biomedical,
Waltham, MA) or mixed 4:1 with nitrite preservation solution4 or centrifuged to isolate plasma
for nitrite measurements. Animals were perfused19 with tissue nitrite preservation solution (1
mM KCN, 0.2% NP-40, 0.8 mM ferricyanide, 0.5 mM NEM, 100 μM DTPA) and brains
homogenized for nitrite measurements. Snap frozen hearts obtained 15 minutes after CPR were
sectioned at −20°C, placed into ice cold nitrite preservation solution and homogenized for
nitrite measurements. All nitrite measurements were determined by tri-iodide based gas-phase
reductive chemiluminescence using an NO analyzer (GE Analytic, Boulder, CO) as described
previously20, 21 and tissue levels normalized to protein content (BCA Protein Assay, Pierce,
Rockford, IL).
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Animals had lines removed, wound closure and chest hair removal before transportation for
echocardiogram 60 minutes after CPR or sham surgery. Animals were secured to the Vevo 770
(VisualSonics, Toronto, ON, Canada) platform and temperature/EKG were monitored
(temperature maintained at >35°C, heart rate >300 beats per minute, supplemental oxygen
delivered via nose cone). Parasternal long-axis 2D images of the left ventricle (LV) were
obtained using the RMV707B scanhead 75–90 minutes post-CPR. M-mode images were used
to measure end-systolic and –diastolic ventricular size and fractional shortening and ejection
fraction (EF) calculated with the manufacturer’s software (v.2.3.0).
Cardiac MRI
Anesthetized animals (1–1.5% isoflurane) were MRI imaged 24 hours post-CPR or sham
surgery. MRI experiments were carried out in a 7.0T, 16-cm horizontal Bruker MR imaging
system (Bruker, Billerica, MA) with Bruker ParaVision 3.0.2 software. Magnevist (Bayer
HealthCare, Montville, NJ) diluted 1:10 with sterile 0.9% saline, was administered
subcutaneously at a dose of 0.3 mmol/kg. Six short axis slices were used to determine EF and
ventricular volumes using CAAS-MRV-FARM software (Pie Medical Imaging, Netherlands).
Histology
Mice were transcardiac perfused with saline followed by 10% buffered formalin19 and brains
removed, further fixed, paraffin-embedded, sectioned and stained with hematoxylin and eosin.
Seven serial high powered (400×) fields of bilateral CA1 at Bregma -1.5 mm were examined
and live and dead cells counted and normalized to hippocampal length as described
elsewhere17.
Mitochondria Isolation
Heart mitochondrial isolation was performed by differential centrifugation as described
elsewhere22 and protein concentration determined. Fresh mitochondria were used for
respirometry, ROS and ATP generation assays and aliquots stored at −80°C for subsequent
Complex I activity assays as described previously23.
Aconitase Activity
Hearts snap frozen 15 minutes after CPR or sham surgery were homogenized in the
manufacturer’s commercial buffer and lysates prepared by three cycles of freeze/thaw.
Aconitase activity was determined spectrophotometrically (340 nm) monitoring NADPH
formation using the Bioxytech Aconitase-340 kit (Oxis Research).
Statistical Analysis
Data appears as means±standard error (SEM) with analysis performed using GraphPad Prism
5 (La Jolla, CA). Continuous data were compared between three groups using one-way
ANOVA with post-hoc Bonferroni adjustment, between two groups using paired Student’s t-
test for variables that are normally distributed and Wilcoxon for variables that are not normally
distributed and for variables measured at multiple time points from same subjects using
repeated measures ANOVA. Mitochondrial experiments were performed as multiple paired
experiments at discrete times and therefore analyzed at each time utilizing a paired t-test.
Mortality was assessed by Kaplan-Meier survival analysis (log rank test). A two-tailed p<0.05
was considered statistically significant
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read and agree to the manuscript as written.
Results
Cardiac arrest physiological effects
Cardiac arrest resulted in metabolic (lactic) and respiratory acidosis and oxygen depletion
(Table 1). Ischemic times and resuscitation rates were similar between groups (Table 2).
Cardiac arrest led to transient hyperemia soon after resuscitation (Figure 1B) as described by
others17. One hour after resuscitation, placebo treated mice exhibited signs of myocardial
depression based on decreased blood pressure, increased tachycardia (Figure 1C) and
decreased ejection fractions (Figure 1D) compared to pre-arrest baseline. Twenty four hours
later LVEF had normalized but right ventricular (RV) failure remained based on RV dilation
and diminished RVEF (Figure 1E). Since right sided pressures were not assessed, it’s unclear
whether this was due to pulmonary hypertension or loss of RV contractility.
Cardiac arrest depletes systemic nitrite which is reversed by IV therapy
Nitrite is reduced to NO and NO-modified proteins during focal ischemia in rodents13, 24. We
tested the hypothesis that basal systemic levels of nitrite would be reduced by ischemic
consumption during cardiac arrest and IV nitrite could restore levels (Figure 2A). In placebo
treated mice, ischemia depleted whole blood nitrite levels (0.64±0.05μM) and nitrite therapy
repleted these levels (1.01±0.06 μM) to near baseline (1.15±0.10μM). These findings were
mirrored in plasma (Figure 2B), heart (Figure 2E/F) and a similar trend noted in brain (Figure
2C). S-nitrosation of the cardiomyocyte L-type calcium channel25 and mitochondrial complex
I23, 25 are protective post-translational modifications resulting from nitrite therapy or ischemic
preconditioning. We found that total S-nitrosothiol modified protein concentration (Figure 2F)
did not change with ischemia but nitrite therapy significantly increased these levels (p<0.05).
Nitrite repletion improves cardiac function
Increased systemic nitrite in treated mice was associated with improved cardiac function. Just
before CPR, animals exhibited similar vascular loading based on identical asystolic pressures
(Table 2). Nitrite didn’t decrease diastolic blood pressure, a coronary perfusion pressure
surrogate, during CPR and ROSC occurred sooner (p=0.034) than placebo treatment.
Consistent with improved cardiac function, nitrite-treated mice exhibited trends towards less
tachycardia than placebo-treated controls (68.7±12.1 vs. 94.7±17.8 beat per minute increase)
and less hypotension (9.1 ± 3.2 vs. 12.6±4.2 mm Hg decrease).
Nitrite significantly improved post-arrest LVEF (54.4±2.4%; Figure 3A/C) compared to
placebo-treated mice (43.5±2.9%; p=0.007). Heart rate and blood pressure were similar
between treatment groups throughout post-ROSC monitoring (data not shown, p>0.2). Given
similar baseline volume loading pre-CPR and similar mean blood pressures prior to imaging,
the LVEF improvements likely indicate improved LV contractility. RVEF measured by MRI
(Figure 3B/D) 24 hours post-CPR was significantly better in nitrite treated mice (54.7±1.3%)
than placebo (42.8±1.7%; p< 0.001). Consistent with improved pulmonary perfusion, gas
exchange 5 minutes post-CPR was improved with nitrite therapy compared to placebo (Table
1).
Nitrite repletion improves survival and survivor neurological function
Death after ROSC occurred 1–6 hours post-CPR after which all animals survived until the
subsequent day (Figure 4). We observed bradycardia and hypotension progressing to asystole
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in mice dying early (while monitored) consistent with death from post-ischemic myocardial
stunning and heart failure. Nitrite therapy significantly improved survival (19/25 [76%])
compared to placebo (12/25 [48%]; hazard ratio 2.72 [95% confidence interval 1.1–6.7];
p=0.033).
Since a third of cardiac arrest survivors have neurological disability, we blindly assigned
neurological scores18 to all 1 day surviving mouse pairs (n=11) (Figure 5A). The median score
for nitrite-treated mice (11) was significantly better than placebo (9; p=0.020). In all pairs,
placebo-treated mice exhibited equal or more severe impairment than nitrite-treated mice. We
measured rectal temperature 22 hours post-resuscitation (Figure 5B) since rodent hypothermia
correlates with severity of injury26. Nitrite-treated mice had better thermoregulation (34.9±0.4°
C) than placebo-treated mice (32.4±0.9°C; p = 0.013). Sham surgery didn’t impair neurological
scores (all 12) or thermoregulation (36.5±0.5°C). Hippocampal CA1, know to be selectively
vulnerable to global ischemia, showed no histological injury at 24 hours consistent with prior
observations27. Seventy-two hour survival experiments were therefore performed (n=3)
demonstrating increased CA1 neuronal injury in placebo- compared to nitrite-treated mice
(Figure 5C, D).
Nitrite specifically and reversibly inhibits complex I
Based on prior observations23, 28 we hypothesized that nitrite therapy in vivo would transiently
S-nitrosate and inhibit mitochondrial complex I resulting in a decrease in reperfusion ROS.
Heart mitochondria from mice treated with nitrite isolated 5, 15 and 60 minutes post-CPR
exhibited reduced state 3 respiration using the complex I substrate pyruvate (Figure 6A) at 5
and 15 minutes but not one hour compared to placebo. Nitrite therapy did not reduce electron
transport efficiency based on respiratory control ratio (5min: 9.5±1.7; 60 min: 13.9±4.4) which
was similar to the placebo-treated group (5min: 7.5±1.0; 60min: 10.4±4.6). Complex II
(succinate) dependent state 3 respiration was similar at all times (Figure 6B) and did not change
with rotenone inhibition (data not shown) indicating nitrite’s complex I specificity. Complex
I activity measured by NADH oxidation at 5 and 60 minutes confirmed the respirometry
findings (Figure 6C). Using pyruvate as substrate, we consistently found increased oxygen
consumption by placebo-treated post-arrest mitochondria compared to pre-arrest despite
reduced complex I (NADH consumption). This suggests pathological oxygen consumption to
form ROS rather than for energy production. Complex I inhibition was reversed 60 minutes
post-CPR as measured by respirometry (Figure 6A) and NADH oxidation (Figure 6C). ATP
generation was similar between 60 minute post-arrest nitrite (58.1±8.1 nmol/min/mg protein)
and placebo (57.1±8.7 nmol/min/mg) treated groups and pre-arrest mice (65.1±4.3 nmol/min/
mg) indicating no persistent functional complex I inhibition.
Nitrite limits reperfusion ROS generation
Consistent with pathological oxygen conversion to ROS, peroxide generation by respiring
mitochondria (pyruvate substrate) 5 and 15 minutes post-CPR exceeded that of pre-arrest mice
but normalized by 1 hour (Figure 7A). Cardiac mitochondria from nitrite-treated mice had
significantly less peak (5 minutes post-CPR) ROS production (14.0±3.2 pmol/min/mg protein)
compared to placebo-treated mice (26.6±4.4 pmol/min/mg; p<0.01). The abundant
mitochondrial enzyme aconitase is susceptible to oxidative modification decreasing its activity
and thus useful as an indicator of oxidative damage. Cardiac arrest significantly decreased
aconitase activity (Figure 7B). Compared to placebo (14.8±8.4 mU/mg protein), nitrite therapy
attenuated this loss of aconitase function (61.6±11.4 mU/mg protein; p=0.05).
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We examine the effects of nitrite repletion on mitochondrial function, reperfusion ROS
generation, organ function and survival in a 12-minute mouse cardiac arrest model. Cardiac
arrest results in systemic nitrite depletion and low dose nitrite replacement (therapy with 50
nmol) at CPR initiation repletes these levels to near baseline and increases cardiac S-nitrothiols.
Therapeutic nitrite repletion and S-nitrosation in heart is associated with transient, reversible
inhibition of complex I reducing mitochondrial reperfusion ROS generation and oxidative
injury. Nitrite improved pulmonary gas exchange, cardiac contractility and survival with a
suggestion of neuroprotection.
Moderate NO reperfusion therapy is known to be protective29 but NO formation is limited by
NO synthase’s dependence on oxygen and reduced substrates30. Nitrite acts as a reservoir for
NO during ischemia and nitrite reduction generates NO through NOS-independent pathways
6, 31, 32. We demonstrate that global ischemia depletes nitrite systemically reducing its
availability to act as a reperfusion NO source. This profound depletion with brief global
ischemia was surprising but not unprecedented13 and explains why our nitrite dose did not
achieve the “optimal” plasma levels (11.9 μM) noted after focal ischemia8. Nitrite repletion
early in reperfusion provides a NOS-independent source of NO to ischemic tissues.
Mitochondrial complexes I and III are major sources of pathological reperfusion ROS 33 and
transient, reversible inhibition of complex I has been proposed as a mechanism to achieve
cardioprotection34–36. The protective effects of complex I inhibition have been described for
nitrite23, S-nitrosothiol donors28 and amobarbital34 and observed during classical ischemic
preconditioning25. Complex I has numerous cysteine residues available for S-nitrosation with
resultant inhibition of electron flow37, 38. Nadtochiy and colleagues S-nitrosated complex I in
cardiomyocytes and isolated heart using S-nitroso-2-mercaptopropionyl glycine with
associated reduction in ROS production and improved cardiac contractility after ischemia-
reperfusion28. Similar to our findings, these authors noted reversal of S-nitrosation and
complex I inhibition 30 minutes after ischemia. Shiva and colleagues provided the first
evidence that nitrite S-nitrosates complex I and reduces ROS production in liver mitochondria
after in vitro ischemia-reperfusion23 though inhibition persisted for 5 hours and was bypassed
via complex II. Sun and colleagues have shown complex I to be one of several proteins S-
nitrosated in cardioprotective ischemic preconditioning 25.
Nitrite therapy is complex I specific based on the lack of effects using succinate. Complex I
efficiency is uneffected therefore this isn’t due to complex I damage. Complex I inhibition is
reversible based on restored oxygen and NADH consumption and ATP generation by 60
minutes. The increase in complex I oxygen consumption with placebo in the absence of
increased NADH oxidation implies pathological oxygen consumption to form ROS rather than
ATP which is prevented with nitrite. Based on our ROS and aconitase data, nitrite is an
antioxidant. This mechanism complements prior observations of reduced tissue nitrotyrosine
staining9, 39, lipid peroxidation9 and superoxide production9 with nitrite therapy.
Cardiac arrest’s poor prognosis is driven primarily by brain and heart injury15. Excepting
hypothermia, no beneficial post-resuscitation therapies exist since CPR’s description ~50 years
ago. Present post-resuscitation care is largely supportive15. Nitrite’s role as a novel therapeutic
would be of great importance in this setting.
Human myocardial dysfunction (stunning) is common cardiac arrest40, 41, ultimately
reversible42 and strongly associated with mortality40, 41 The molecular mechanisms of
myocardial stunning after cardiac arrest remain unknown but loss of excitation-contraction
coupling is believed to result from ROS injury and calcium-mediated proteolysis43. Nitrite, by
reducing ROS, may mitigate stunning similar to other antioxidants44. The reduction in
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myocardial dysfunction likely explains the 50% relative survival advantage we noted. Further
work is needed to characterize nitrite’s effects on brain injury but our results are encouraging.
We designed a mouse model of cardiac arrest with prolonged asystole to study the effects of
nitrite on heart and brain injury after resuscitation. Our model utilizes hyperkalemia to induce
arrest, limiting its clinical relevance and potentially causing artifacts which may be organ
protective (eg cardioplegia) or injurious (endothelial damage perhaps causing RV dysfunction).
In the context of these limitations, we demonstrate improvements in gas exchange, heart and
brain function and survival. We demonstrate that nitrite transiently inhibits complex I resulting
in an antioxidant effect. The ease in delivering IV nitrite,, its established human safety14, 31,
its reproducible cytoprotective effects in multiple organs and species6 all suggest that nitrite
represents a promising post-resuscitation therapy after cardiac arrest.
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Figure 1. Cardiac arrest experiment, endpoints and cardiovascular effects
(A) Experimental outline with sample blood pressure and EKG pre-arrest, during arrest,
cardiopulmonary resuscitation (CPR), return of spontaneous circulation (ROSC) and recovery
phases with endpoints. (B) Physiological data from one experiment depicting heart rate (HR),
mean arterial blood pressure (MAP) and exhaled carbon dioxide (CO2). The ischemic period
is shaded. (C–E) Post-arrest placebo treated mice are compared to non-arrested shams. (C)
Mean HR increases and MAP decreases 60 min post-CPR vs. 1 min pre-arrest (n=21). (D)
Cardiac arrest results in significant reductions in left ventricular fractional shortening (FS) and
ejection fraction (EF) by echocardiography 75–90 minutes post-CPR (n=6). (E) Cardiac arrest
results in diminished right ventricular ejection fraction (RVEF) and increased dilation
(RVEDV: RV end-diastolic volume; n=5). Values denoted as means±SEM analyzed by paired
t-test; *, p<0.01; †, p=0.038.
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Figure 2. Systemic nitrite depletion after global ischemia and therapeutic repletion
Whole blood (A) and plasma (B) nitrite levels (n=6) measured after 12 minutes of global
ischemia and 5 minutes reperfusion are depleted in placebo vs. sham, and nitrite therapy
increases levels with similar trends in brain (C). (D) A sample reductive chemiluminescence
tracing measuring nitrite in heart 15 min after CPR. Peaks represent total tissue nitrite (first
peak), S-nitrosothiols (second peak) and the mercury stable fraction (third peak; not visible).
(D) Ischemia depletes heart nitrite in placebos and nitrite therapy significantly increases total
levels and (E) S-nitrosothiols (n=7). Values denoted as means±SEM analyzed by ANOVA; *,
p<0.01 (placebo vs. sham); †, p<0.01 and ‡, p<0.05 (nitrite vs. placebo).
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Figure 3. Improved cardiac function after nitrite therapy
(A) Sample M-mode echocardiogram images obtained 75–90 minutes post-CPR from a pair
of mice randomized to placebo (n=6) or nitrite therapy (n=8). (C) Left ventricular ejection
fraction (LVEF) was significantly improved with nitrite therapy. (B) Sample MRI images 24
hours after CPR demonstrate normal LVEF but a dilated right ventricle with improved right
ventricular ejection fraction (RVEF) in nitrite-treated vs. placebo animals (n=5). Values
denoted as means±SEM analyzed by paired t-test; *, p<0.01.
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Figure 4. Nitrite therapy improves survival
After resuscitation, animals died 1–6 hours after CPR. Nitrite improved 22 hour survival
compared to placebo (*, p=0.033; n=28/27 for placebo/nitrite groups).
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Figure 5. Nitrite neuroprotection
Neurological function in paired 22 hour survivors (n=11) was improved with nitrite based on
(A) neurological scores and (B) thermoregulation (rectal temperature). (C) At 72 hours post-
CPR, moderate to severe hippocampal CA1 cell death was noted in placebo-treated brains
while lesser injury was noted in nitrite-treated survivors. Hematoxylin and eosin staining, bar
indicates 40 μm. (D) Summary of live and dead cells (per millimeter of CA1) in serial high-
powered fields. Data presented as median (A) or means±SEM (B,D); *, p=0.016; †, p=0.013;
‡, p<0.01; #, p<0.05 comparing nitrite to placebo.
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Figure 6. Nitrite therapy effects on mitochondrial function
Heart mitochondrial respiration time course where zero represents CPR start and shaded area
indicates arrest. (A) Inhibition of pyruvate (complex I) mediated respiration was present at 5
(n=8) and 15 minutes (n=4) post-CPR but reversed by 1 hour. (B) Succinate (complex II)
mediated respiration rates did not differ (n ≥ 4 for each time). Inset: sample traces of
mitochondrial oxygen consumption 5 minutes post-CPR. (C) Complex I activity measured in
sub-mitochondrial particles by NADH oxidation. Compared to placebo, nitrite therapy
significantly reduced complex I activity 5 minutes post-CPR (n=7) which was reversed by 60
minutes. Inset: sample tracing 5 minutes post-CPR. Values denoted as means±SEM, analyzed
at each time by paired t-test; *, p<0.01; †, p=0.021; ‡, p=0.014.
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Figure 7. Nitrite therapy effects on mitochondrial oxidative burst and injury
(A) Reactive oxygen species (ROS) generation was measured as mitochondrial peroxide
production using the Amplex Red assay. Cardiac arrest increased ROS at 5 and 15 minutes
which resolved by 60 minutes. Compared to placebo, nitrite reduced ROS production 5 minutes
(n=7) after CPR with a similar trend at 15 minutes (n=4). (B) Cardiac arrest resulted in a
significant loss of heart aconitase activity which improves with nitrite therapy. Inset: sample
trace from each group. Values denoted as means±SEM, analyzed by paired t-test (ROS) or
ANOVA (aconitase); *, p<0.01; †, p=0.071; ‡, p<0.01 sham (n=11) vs. placebo(n=8); #, p=0.05
nitrite (n=8) vs. placebo.
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Table 1
Arterial blood gas results obtained from sham mice or five minutes after CPR from mice randomized to placebo or
nitrite
Post-Arrest Treatment
Characteristic Sham Placebo Nitrite
pH 7.35±0.03 6.61±0.04 * 6.73±0.05
PaCO2 (mm Hg) 38.4±2.7 108.3±16.0 * 66.2±16.2 **
PaO2 (mm Hg) 253.7±17.6 128.2±23.8 * 210.7±25.7 **
Bicarbonate (mg/dL) 20.9±0.8 9.9±0.9 * 8.4±0.9
Lactate (mg/dL) 0.9±0.1 16.5±0.5 * 15.6±1.2
Key: All data means±SEM (n=5 per group) analyzed by ANOVA;
*
, p<0.01 sham vs. post-arrest placebo;
**
, p<0.05 post-arrest placebo vs. nitrite.
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Table 2
Baseline and CPR characteristics of randomized animals
Post-Arrest Treatment
Characteristic Placebo Nitrite
Age at Experiment (weeks) 10±1.8 10±1.8
Weight (g) 27.0±2.3 26.5±2.3
Ischemic Time (min) 12.0±0.01 12.0±0.03
DBP 15 sec prior to CPR 4.3±0.4 4.8±0.2
DBP during 15 sec after CPR start 27.4±2.3 27.9±3.5
Successful Resuscitation 25/28 (89%) 25/27 (93%)
Time to ROSC (sec) 54.8±30.1 43.0±26.3*
Key:
*
, p=0.034; DBP=diastolic blood pressure; ROSC=return of spontaneous circulation; n=21 per group
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